CagriSema, Novo Nordisk's experimental weekly injection, delivered an estimated average weight loss of 12.4% in a late-stage trial involving patients with diabetes, compared with 9.1% for Eli Lilly's tirzepatide. The 1 mg CagriSema dose was superior to tirzepatide at 5 mg for weight loss, while producing non-inferior blood-sugar reduction, meaning it was no worse on that measure. CagriSema combines cagrilintide, which mimics the pancreatic hormone amylin, with semaglutide, the active ingredient in Wegovy. The drug is viewed as a successor to Wegovy, whose patents face expiries after 2030. The result follows a setback earlier this year, when CagriSema fell short of Lilly's Zepbound in a head-to-head weight-loss trial.